{"title": "Disfiguring eye symptoms diminish in Graves' eye disease drug trial", "text": "", "article_link": null, "url": "http://www.eurekalert.org/pub_releases/2017-05/mmu-des042817.php", "region": "namerica", "source_link": null, "funder": "River Vision Development, US Food and Drug Administration, National Institutes of Health, and others", "meeting": "", "institution": "Michigan Medicine - University of Michigan", "keywords": ["Medicine/Health", " Clinical Trials", " Endocrinology", " Ophthalmology"], "journal": "New England Journal of Medicine", "description": "Graves' eye disease, also known as thyroid eye disease, takes a physical and emotional toll on patients as inflammation and tissue buildup cause the eyes to bulge painfully from their sockets. A new clinical trial led by the University of Michigan Kellogg Eye Center shows a failed cancer drug can successfully reduce eye symptoms and improve quality of life for TED patients.", "date": "Wed, 03 May 2017 04:00:00 GMT"}